Structured evidence table for Chromium Triglycerides Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Chromium Triglycerides Randomized Trial | 1 1 2 Table 1 Aspect Details References Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Triglycerides Randomized Trial | 1 [] Common risk factors include obesity (BMI ≥ 25 kg/m), increased waist circumference (>102 cm for men, >88 cm for women), hypertension, smoking, hyperlipidemia, age > 40 years, and a history of gestational diabetes. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Triglycerides Randomized Trial | 5 [] Metabolic syndrome increases the risk of cardiovascular diseases, kidney disease, eye problems, neuropathy, and diabetes-related complications such as foot ulcers and amputations. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Triglycerides Randomized Trial | It includes central obesity, insulin resistance, hypertension, and dyslipidemia. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Triglycerides Randomized Trial | Mineral supplementation was associated with significant reductions in fasting blood glucose (SMD = − 0.34, p < 0.001), fasting insulin (SMD = − 0.72, p < 0.001), and HOMA-IR (SMD = − 0.75, p < 0.001). | 1 | Ye J (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. |
| Chromium Triglycerides Randomized Trial | In addition, total cholesterol (SMD = − 0.35, p < 0.001) and triglyceride levels (SMD = − 0.58, p < 0.001) were significantly reduced. | 1 | Ye J (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. |
| Chromium Triglycerides Randomized Trial | CONCLUSION: Mineral supplementation may improve insulin resistance and selected metabolic parameters in PCOS, with the most consistent effects observed for glycemic indices. | 1 | Ye J (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. |
| Chromium Triglycerides Randomized Trial | BACKGROUND: Polycystic ovary syndrome (PCOS) often leads to insulin resistance, affecting glucose and fat metabolism. | 1 | Ye J (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. |
Source documents